What the business is, and whether it's a good one at a fair price.
Develops, manufactures, and sells branded pharmaceutical formulations in India and international markets, with a contract development and manufacturing (CDMO) arm serving major global OTC customers. The India branded formulations business is the largest stream at ₹2,461 cr in FY26 (branded formulations grew 11%), focused on chronic therapies where the business grew 19% against IPM growth of 14%. International formulations generated ₹1,154 cr in FY26 across 40+ countries, while the CDMO segment earned ₹445 cr. The company manufactures oral solids (58% of BRSR turnover mix), injectables, liquids, and medicated lozenges, and is among the top five global manufacturers of medicated lozenges. It runs 8 manufacturing plants in India, serves 28 states domestically plus 40+ countries, and exports contribute 35% of total turnover. Major cost items are materials at ₹912.44 cr (22% of revenue), employee costs at ₹772.7 cr (18.6%), and other operating expenses at ₹971.39 cr (23.4%). In January 2026, Torrent Pharmaceuticals acquired a controlling stake and the company was amalgamated into Torrent effective 8 July 2026, with JB Chemicals dissolved without being wound up.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from J B CHEMICALS AND PHARMA's filed financials and exchange disclosures
J B CHEMICALS AND PHARMA is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol JBCHEPHARM.
Yes. Over the trailing twelve months J B CHEMICALS AND PHARMA reported a net profit of ₹709 Cr on revenue of ₹4,148 Cr.
Yes. It paid out 44% of its profit as dividend in FY26.
Effectively yes. It holds ₹110 Cr more cash than debt. Debt stands at 0.00× equity.
Every NSE and BSE filing by J B CHEMICALS AND PHARMA appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
